Karel Allegaert1,2, Amir Lahav3, John N van den Anker4,5,6. 1. Intensive Care and Department of Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. karel.allegaert@uzleuven.be. 2. Department of Development and Regeneration, KU Leuven, Leuven, Belgium. karel.allegaert@uzleuven.be. 3. Department of Pediatrics, Mass General Hospital for Children, Harvard Medical School, Boston, MA, 02114, USA. 4. Intensive Care and Department of Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 5. Division of Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland. 6. Division of Clinical Pharmacology, Children's National Health System, Washington, DC, USA.
Authors: Ronit M Pressler; Geraldine B Boylan; Neil Marlow; Mats Blennow; Catherine Chiron; J Helen Cross; Linda S de Vries; Boubou Hallberg; Lena Hellström-Westas; Vincent Jullien; Vicki Livingstone; Barry Mangum; Brendan Murphy; Deirdre Murray; Gerard Pons; Janet Rennie; Renate Swarte; Mona C Toet; Sampsa Vanhatalo; Sarah Zohar Journal: Lancet Neurol Date: 2015-03-10 Impact factor: 44.182